Clinical Trial Update: A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia [Phase 3]

View source ↗

Summary

Phase 3 trial of olezarsen administered subcutaneously in adults with severe hypertriglyceridemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• Olezarsen (olezarsen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Severe Hypertriglyceridemia | Phase 3 | Status: COMPLETED